Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
13/05/2026 11:50
May 13 (Reuters) - Protalix BioTherapeutics Q1 operating income USD 21.146 million. Q1 net income USD 18.317 million Q1 pretax profit USD 21.141 million
Recent news on Protalix BioTherapeutics
See all newsIsrael's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlook
Israel's Protalix Q1 revenue surges on Chiesi milestone
Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio